These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 30593515)

  • 1. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.
    Ahn B; Kim D; Park KJ; Park JM; Yoon SY; Hong B; Cho YM; Kim D
    Cancer Res Treat; 2024 Jul; 56(3):856-870. PubMed ID: 38147818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Wang F; Dong X; Yang F; Xing N
    Front Genet; 2022; 13():831146. PubMed ID: 35419031
    [No Abstract]   [Full Text] [Related]  

  • 4. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy.
    Martini A; Lonati C; Montorsi F; Briganti A; Colombo R; Necchi A; Simeone C; Zamboni S; Afferi L; Mattei A; Carando R; Ploussard G; Soria F; Marra G; Rouprêt M; Xylinas E; Pradere B; Abufaraj M; D'Andrea D; Shariat SF; Moschini M
    Clin Genitourin Cancer; 2022 Jun; 20(3):e190-e198. PubMed ID: 35105509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
    Winters BR; De Sarkar N; Arora S; Bolouri H; Jana S; Vakar-Lopez F; Cheng HH; Schweizer MT; Yu EY; Grivas P; Lee JK; Kollath L; Holt SK; McFerrin L; Ha G; Nelson PS; Montgomery RB; Wright JL; Lam HM; Hsieh AC
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31145100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.
    Wu S; Chen J; Dong P; Zhang S; He Y; Sun L; Zhu J; Cheng Y; Li X; Tang A; Huang Y; Gui Y; Liu C; Yang G; Zhou F; Cai Z; Wang R
    BMC Cancer; 2014 Nov; 14():836. PubMed ID: 25408144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
    Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.
    Setti Boubaker N; Cicchillitti L; Said R; Gurtner A; Ayed H; Blel A; Karray O; Essid MA; Gharbi M; Bouzouita A; Rammeh Rommeni S; Chebil M; Piaggio G; Ouerhani S
    Mol Biol Rep; 2019 Oct; 46(5):4743-4750. PubMed ID: 31214962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.